Suppr超能文献

非典型腺细胞的报告率及其HPV检测和组织学随访结果:来自单一学术机构的ThinPrep和SurePath制片方法的比较

The reporting rates of atypical glandular cells and their HPV testing and histologic follow-up results: a comparison between ThinPrep and SurePath preparations from a single academic institution.

作者信息

Liu Shiguang, Gibbons-Fideler I-Sanna, Tonkovich Dena, Shen Rulong, Li Zaibo

机构信息

Department of Pathology, The Ohio State University Wexner Medical Center, Columbus, Ohio.

Department of Pathology, The Ohio State University Wexner Medical Center, Columbus, Ohio.

出版信息

J Am Soc Cytopathol. 2019 May-Jun;8(3):128-132. doi: 10.1016/j.jasc.2018.11.003. Epub 2018 Nov 29.

Abstract

INTRODUCTION

The interpretation of atypical glandular cells (AGCs) remains a major challenge in gynecologic cytopathology using liquid-based cytology (LBC) (ThinPrep and SurePath). The comparison of performance of detecting glandular abnormalities using these 2 methods is lacking. We investigated the reporting rates of AGCs, human papillomavirus (HPV) testing, and histologic follow-up results in ThinPrep (TP) and SurePath (SP) samples.

MATERIALS AND METHODS

In our institution, both TP and SP were utilized during the period between January 2014 and June 2017. A retrospective search was conducted to identify patients with AGCs from 58,591 LBCs (27,041 TP and 31,550 SP). Roche (Pleasanton, CA) cobas HPV testing and histologic follow-up results were collected.

RESULTS

The reporting rates of AGCs for TP (0.7%) or SP (0.2%) were within the College of American Pathologists benchmark ranges, but the reporting for TP was significantly greater than that for SP (P < 0.0001). The HPV-positive rates were 26.0% and 19.4% in TP-AGCs and SP-AGCs, respectively, with no statistical significance. A total of 137 (74.9%) TP-AGCs and 54 (74%) SP-AGCs had histologic follow-up. High-grade squamous intraepithelial lesions (HSIL)/squamous cell carcinoma were identified in 8.8% (12 of 137) of TP-AGCs and 13% (7 of 54) of SP-AGCs. Adenocarcinomas including endocervical and endometrial adenocarcinomas were identified in 9.5% (13 of 137) of TP-AGCs and 13% (7 of 54) of SP-AGCs. Together, 18.2% (25 of 137) of TP-AGCs and 25.9% (14 of 54) of SP-AGCs showed either HSIL or carcinoma in histologic follow-up, but with no statistical significance.

CONCLUSIONS

TP preparation detected considerably more AGCs than SP preparation. There was no statistical significant difference in HPV-positive rates or histologic follow-up outcomes between TP-detected AGCs and SP-detected AGCs.

摘要

引言

在使用液基细胞学(LBC)(ThinPrep和SurePath)的妇科细胞病理学中,非典型腺细胞(AGC)的解读仍然是一项重大挑战。目前缺乏对使用这两种方法检测腺性异常的性能比较。我们调查了ThinPrep(TP)和SurePath(SP)样本中AGC的报告率、人乳头瘤病毒(HPV)检测情况以及组织学随访结果。

材料与方法

在我们机构,2014年1月至2017年6月期间同时使用了TP和SP。进行回顾性检索,从58591例LBC样本(27041例TP和31550例SP)中识别出AGC患者。收集了罗氏(加利福尼亚州普莱森顿)cobas HPV检测结果和组织学随访结果。

结果

TP(0.7%)或SP(0.2%)的AGC报告率在美国病理学家学会的基准范围内,但TP的报告率显著高于SP(P < 0.0001)。TP-AGC和SP-AGC的HPV阳性率分别为26.0%和19.4%,无统计学意义。共有137例(74.9%)TP-AGC和54例(74%)SP-AGC进行了组织学随访。在TP-AGC中,8.8%(137例中的12例)发现高级别鳞状上皮内病变(HSIL)/鳞状细胞癌,在SP-AGC中为13%(54例中的7例)。在TP-AGC中,9.5%(137例中的13例)发现包括宫颈管腺癌和子宫内膜腺癌在内的腺癌,在SP-AGC中为13%(54例中的7例)。总体而言,在组织学随访中,18.2%(137例中的25例)的TP-AGC和25.9%(54例中的14例)的SP-AGC显示HSIL或癌,但无统计学意义。

结论

TP制片检测到的AGC比SP制片多得多。TP检测到的AGC和SP检测到的AGC在HPV阳性率或组织学随访结果方面无统计学显著差异。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验